Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imipenem/cilastatin/relebactam versus colistimethate sodium + imipenem/cilastatin for imipenem-resistant bacterial infection
2015-000066-62Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of imipenem + cilastatin + relebactam in bacterial disease, hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) and 3 more (3 arms), sponsored by Merck & Co. Primary endpoint: Primary efficacy endpoint: overall response. Started Mar 2015; status: completed.
02
Drugs
imipenem + cilastatin + relebactam
03
Conditions
bacterial diseasehospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)complicated urinary tract infection (cUTI)
Beyond the preview
Go deeper on 2015-000066-62.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000066-62.